SCHEMBL14833019

SCHEMBL14833019

Cn1cc2c(n1)c(Cl)nc1ncc(Cl)cc12

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 9/20 0.64
HRH3 Q9Y5N1 3/20 0.64
ADORA2A P29274 5/20 0.40
ADORA1 P30542 3/20 0.40
MAT2A P31153 3/20 0.34
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ADORA3 P0DMS8 3/20 0.31
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
PABPC1 P11940 1/20 0.30
KMT2A Q03164 1/20 0.30
KDM4E B2RXH2 1/20 0.30
HCRTR1 O43613 1/20 0.30
MAPT P10636 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14833021 0.79 HRH4 (1.00) HRH4HRH3
SCHEMBL14833018 0.77 HRH4 (0.79) HRH4HRH3
SCHEMBL14839217 0.75 HRH4 (0.69) HRH4HRH3
SCHEMBL406003 0.74 ADORA2A (0.47) HRH4HRH3ADORA2AADORA1MAT2A
SCHEMBL27961253 0.70 HRH4 (0.45) HRH4HRH3MAT2AHPGDHTT
SCHEMBL3454725 0.67 LMNA (0.41) HRH4HRH3HTTHSD17B10MEN1
SCHEMBL17083434 0.67 MAOA (0.46) ADORA2AADORA1ADORA3MEN1KMT2A
SCHEMBL14833035 0.67 HRH4 (0.34) HRH4HRH3LMNAKMT2A
SCHEMBL406065 0.67 LMNA (0.45) HRH4ADORA2AADORA1HTTADORA3
SCHEMBL25375323 0.66 ADORA2A (0.38) HRH4HRH3ADORA2AADORA1MAT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3461825-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C Research Laboratories (KR) 2019-04-03 EP disclosed
EP-2760865-B1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RES LAB (KR) 2018-07-11 EP disclosed
US-9586959-B2 Substituted tricyclic heterocycles as histamine 4 receptor inhibitors C&C RESEARCH LABORATORIES (KR) 2017-03-07 US disclosed
US-20140315888-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RESEARCH LABORATORIES (KR) 2014-10-23 US disclosed
EP-2760865-A2 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C Research Laboratories (KR) 2014-08-06 EP disclosed
WO-2013048214-A2 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RESEARCH LABORATORIES (KR) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315888-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES HRH4, HRH2, HRH1 HRH4 1/4885HRH3 4/4885ADORA2A 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.